EDIT Editas Medicine Inc.

Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference

Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the Company’s President and CEO Gilmore O’Neill, M.B., M.M.Sc., will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, 4:30 p.m. PT / 7:30 p.m. ET in San Francisco, CA.

A live webcast of the presentation will be available on the “Investors” section of the Editas Medicine website at . An archived replay will be available on the website for approximately 30 days following the presentation.

About Editas Medicine

As a clinical stage genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute and Harvard University’s Cas9 patent estates and Broad Institute’s Cas12a patent estate for human medicines. For the latest information and scientific presentations, please visit .

Contacts:

Media

Cristi Barnett

(617) 401-0113

Investors:

Ron Moldaver

(617) 401-9052



EN
04/01/2023

Underlying

EDITEditas Medicine Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Editas Medicine Inc.

 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine Announces EDIT-401 Oral Presentation at the European S...

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced an oral presentation at the upcoming European Society of Gene and Cell Therapy (ESGCT) Congress, to be held October 7-10, 2025, in Seville, Spain. European Society of Gene and Cell Therapy (ESGCT) Congr...

1h / 10m 1 EN
 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead...

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into second quarter of 2027 Company-sponsored webinar on EDIT-401 today at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced the nomination of its lead in vivo development candidate, EDIT-401,...

September 2, 2025 1 EN
 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Ca...

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will host a webinar on Tuesday, September 2, 2025, at 8:00 a.m. ET to announce the selection of its lead in vivo development candidate. Webinar Presentation Details:The live and archived webcast of the Company’s webinar presentation will be accessible through this , or through the page of the “Inv...

August 28, 2025 1 EN
 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine to Participate in Upcoming Investor Conferences

Editas Medicine to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in September: Wells Fargo Healthcare ConferenceFormat: One-on-one MeetingsDate: Wednesday, September 3Location: Boston, MA Cantor Global Healthcare ConferenceFormat: Fireside Chat with Webcast and One-on-one MeetingsDate: Thursday, Septembe...

August 27, 2025 1 EN
 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine Announces Second Quarter 2025 Results and Business Upd...

Editas Medicine Announces Second Quarter 2025 Results and Business Updates Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026 First IND/CTA accepted for CD19 HD Allo CAR T program as part of collaboration with Bristol Myers Squibb, triggering milestone payment to Editas Presented data at ASGCT, TIDES, and EHA that validate differentiated potential of Editas’ gene upregulation strategy and in vivo delivery platform technology ​ Strong cash position with operational runway into the se...

August 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch